Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2206945 | 0.89 | SMN1; SMN2 (0.46) | USP2SMN1; SMN2HPGDEPHX1ADORA1 | |
| SCHEMBL605185 | 0.85 | USP2 (0.43) | USP2SMN1; SMN2HPGDADORA1L3MBTL1 | |
| SCHEMBL25737087 | 0.84 | USP2 (0.42) | USP2SMN1; SMN2HPGDEPHX1ADORA1 | |
| SCHEMBL15958599 | 0.84 | USP2 (0.42) | USP2SMN1; SMN2HPGDGAAADORA1 | |
| SCHEMBL24940831 | 0.83 | USP2 (0.41) | USP2SMN1; SMN2HPGDADORA1L3MBTL1 | |
| SCHEMBL17113616 | 0.82 | SMN1; SMN2 (0.43) | USP2SMN1; SMN2HPGDGAADDB1 | |
| SCHEMBL6992779 | 0.81 | USP2 (0.42) | USP2SMN1; SMN2HPGDADORA1L3MBTL1 | |
| SCHEMBL30229162 | 0.81 | TSHR (0.39) | USP2SMN1; SMN2HPGDDDB1CRBN | |
| SCHEMBL24192983 | 0.81 | TSHR (0.39) | USP2SMN1; SMN2HPGDDDB1CRBN | |
| SCHEMBL24940829 | 0.80 | USP2 (0.38) | USP2SMN1; SMN2ADORA1TSHRALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2170850-B1 | NOVEL DICARBOXYLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS | BIOPROJET SOC CIV (FR) | 2014-09-24 | — | — | EP | disclosed |
| EP-2170850-B1 | NOVEL DICARBOXYLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS | BIOPROJET SOC CIV (FR) | 2014-09-24 | — | — | EP | disclosed |
| US-8809539-B2 | Dicarboxylic acid derivatives as S1P1 receptor agonists | BIOPROJET (FR) | 2014-08-19 | — | — | US | disclosed |
| US-8809539-B2 | Dicarboxylic acid derivatives as S1P1 receptor agonists | BIOPROJET (FR) | 2014-08-19 | — | — | US | disclosed |
| US-20100249187-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS | BIOPROJET (FR) | 2010-09-30 | — | — | US | disclosed |
| US-20100249187-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS | BIOPROJET (FR) | 2010-09-30 | — | — | US | disclosed |
| EP-2170850-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS | BIOPROJET (FR) | 2010-04-07 | — | — | EP | disclosed |
| WO-2008152149-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS | BIOPROJET (FR) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249187-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS | S1PR1, S1PR2, S1PR5 | USP2 4600/4885SMN1; SMN2 3276/4885HPGD 1618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.